CDYL2

Across TCGA pan-cancer cohorts, CDYL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDYL2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDYL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDYL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where CDYL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	1.000	0.804	.015	6	view →
CCRCC	DFS	Median	IV	0.887	0.198	.024	6	view →
LUAD	OS	Quartile	All	0.731	0.920	.024	4	view →
LSCC	OS	Quartile	All	0.751	0.919	.029	3	view →
PDAC	OS	Median	II,III,IV	0.981	0.743	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDYL2–UCEC (DFS)

Open the UCEC breakdown →